Plastoquinone PQ10.

Plastoquinone and ubiquinone are the same class of lipid-soluble benzoquinone electron carrier, differing in their ring substituents and prenyl chain length. Both cycle between quinone and quinol and quench lipid radicals by the same hydrogen-donating step.

SkQ1 is plastoquinone joined to a lipophilic cation so the molecule accumulates in mitochondria. The redox-active head group is the same one plastoquinone carries.

Plastoquinone and tocopherol are both built in plants from homogentisate and sit in the same membranes quenching lipid peroxyl radicals. The plastoquinol form can hand electrons into the same chain that regenerates tocopherol.

Ascorbate is the water-phase reductant that returns oxidised lipid-phase antioxidants to their active form at the membrane surface. That is the same service it performs for tocopherol and ubiquinone.

Plastoquinone has a long isoprenoid tail and essentially no water solubility, the same handling problem ubiquinone presents. A medium chain triglyceride carrier keeps it in solution in a softgel and provides the lipid load that triggers bile release and micelle formation. This is a delivery relationship, not a physiological one.

Emulsifying a prenylquinone with phospholipid lowers particle size and raises the surface area presented to bile salts, which is how ubiquinone formulations address the same solubility limit. Lecithin also stabilises the oil interface against oxidation. The benefit is dispersion, and it says nothing about what the quinone does once absorbed.

Bile salts form the mixed micelles that ferry lipophilic quinones across the intestinal water layer. Where bile is limited, the absorbed fraction of an already poorly absorbed molecule falls further. The point is a requirement of the absorption route rather than an added benefit.

Quinones cycle between oxidised quinone and reduced quinol, and reducing equivalents come from thiol and pyridine nucleotide pools. Dihydrolipoate is a strong reductant that participates in that network. The pairing is chemically coherent and is not backed by a human trial cited here.

A lipid phase antioxidant only keeps working if something regenerates its reduced form, and the glutathione pool is the main cellular reservoir that does this, directly or through intermediaries. Plastoquinol, like ubiquinol, is the active reduced species. This describes network chemistry and is not evidence of a combined effect in people.

Cysteine availability is the rate limiting input to glutathione synthesis, and glutathione underwrites the reduction of quinones and tocopheroxyl radicals. Supporting the thiol pool is therefore upstream of any lipid phase antioxidant. The chain of reasoning is mechanistic and has several steps in it, so confidence is held down accordingly.

Astaxanthin spans the membrane bilayer and quenches radicals within it, while a prenylquinone sits in the hydrophobic core and cycles between quinone and quinol. The two occupy overlapping but not identical positions in a membrane. Additivity here is a chemical expectation, not a measured result.

Piperine is used in formulations to raise the measured blood levels of poorly absorbed lipophilic compounds by slowing their conjugation and efflux. Whether it does this for a plastoquinone specifically has not been shown, so the row is a mechanistic candidate rather than a demonstrated pairing. Piperine also raises the exposure of unrelated co-administered substances, which is a reason for care rather than enthusiasm.

Menaquinone-7 and plastoquinone are both prenylquinones, differing in ring system and tail length, and both cycle through a reduced quinol state. That shared chemistry means they may compete for the same reductases and membrane positions rather than simply add together. The interaction is structural and has not been measured in people.